Business Context and Reporting Period
This Form 8-K Current Report is filed by Imprimis Pharmaceuticals, Inc. (noted as Harrow, Inc. in metadata) on March 11, 2016. The filing reports the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Public offering of 2.9 million shares of Common Stock ($0.001 par value).
- Offering Price: $3.60 per share.
- Underwriters: National Securities Corporation (sole book-running manager) and Sterne Agee CRT (co-manager).
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to an additional 15% of shares (approx. 435,000 shares) to cover over-allotments.
- Expected Net Proceeds: Approximately $9.7 million from the base offering; approximately $11.1 million if the over-allotment option is exercised in full.
- Expected Closing Date: March 16, 2016, subject to customary conditions.
Material Changes
The filing does not report changes to historical revenue, profit, or operating margins. The primary material change is the anticipated increase in liquidity and cash reserves resulting from the equity offering described above.
Outlook, Risks, and Management Commentary
The Company intends to use the net proceeds to fund its operations and advance its product development. The filing notes that the Underwriting Agreement contains customary representations, warranties, indemnification obligations, and termination provisions. The document explicitly states it is not intended to provide factual information about the Company beyond the terms of the agreement.
Investor Verification Checklist
- Verify the final closing date of the offering (expected March 16, 2016).
- Confirm whether the underwriters exercised the 15% over-allotment option.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific use of proceeds and covenants.
- Check subsequent filings for the actual net proceeds received after deducting all offering expenses.